These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29338553)

  • 1. Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.
    Bassiouny D; Ismiil N; Dubé V; Han G; Cesari M; Lu FI; Slodkowska E; Parra-Herran C; Chiu HF; Naeim M; Li N; Khalifa M; Nofech-Mozes S
    Int J Surg Pathol; 2018 Jun; 26(4):306-317. PubMed ID: 29338553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
    Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
    Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
    Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
    BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
    Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
    Schmoeckel E; Kirchner T; Mayr D
    Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases.
    Raspollini MR; Amunni G; Villanucci A; Baroni G; Taddei A; Taddei GL
    Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):127-31. PubMed ID: 15354737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
    Ates Ozdemir D; Usubutun A
    Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
    Saied EM; El-Etreby NM
    Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
    Chiesa-Vottero A
    Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
    Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
    BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas.
    Carleton C; Hoang L; Sah S; Kiyokawa T; Karamurzin YS; Talia KL; Park KJ; McCluggage WG
    Am J Surg Pathol; 2016 May; 40(5):636-44. PubMed ID: 26685087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.